IRIDEX Corp (IRIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.70-0.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · IRIX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.2% |
| Our one-year growth estimate | diamond | 9.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 97.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
IRIX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-02
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, IRIDEX Corporation (the “Company”) received a notification of non-compliance (the “Notice”) from Nasdaq’s Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement fo…
Why it matters: Reaching cash flow breakeven is important for financial stability. It shows good cost management.
Supportive ifThe company reports cash flow breakeven for the first half of 2026.
Worry ifCash flow remains negative for the first half of 2026.
Why it matters: If health care revenue growth speeds up, it may help IRIDEX's performance. A strong sector can lift all companies.
Supportive ifHealth care revenue growth speeds up to 10% or more.
Worry ifHealth care revenue growth keeps slowing down below current levels.
Why it matters: Reaching cash flow breakeven is important for financial health. It shows the company controls costs well.
Supportive ifManagement reports cash flow breakeven achieved or on track in the next earnings call.
Worry ifManagement states cash flow breakeven is delayed beyond 2025.
Why it matters: More sales of Cyclo G6 are vital to offset losses in other products.
Supportive ifCyclo G6 product family revenue grows above $3.9 million in Q3.
Worry ifCyclo G6 revenue falls below $3.9 million in Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$120 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $531 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,513 loss on $10,000 · 55.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Meeting this revenue target would show growth momentum and support annual guidance.
Supportive ifQ2 2026 revenue reported at $12 million or more.
Worry ifQ2 2026 revenue reported below $11 million.
Why it matters: Keeping expenses in check is important for better margins. It impacts overall profit.
Watch forManagement says they will cut operating costs by 10% or more in Q3 2026.
Also watch forOperating expenses increase by 5% or more in Q3 2026.
Why it matters: Positive cash flow shows the turnaround strategy is working.
Supportive ifCompany reports positive cash flow for Q2 2026.
Worry ifCompany reports continued negative cash flow for Q2 2026.
Why it matters: Stable revenue in the retina segment shows recovery from recent issues. This could mean better sales.
Supportive ifQ3 retina product revenue is over $6 million. This shows recovery from past drops.
Worry ifQ3 retina product revenue is under $6 million. This shows ongoing problems.
Why it matters: Positive cash flow would show that management's changes and cost controls are working.
Supportive ifQ3 operating cash flow is positive. This shows good cost management.
Worry ifQ3 operating cash flow is negative. This shows ongoing financial problems.
Why it matters: Fixing the Nasdaq compliance issue is important. It helps keep the company's listing and investor trust.
Worry ifNasdaq confirms compliance with listing standards. This lifts the delisting notice.
Less concerning ifNasdaq sends another notice of non-compliance. This raises delisting risk.